China overtakes Europe in healthcare investing sentiment
China has overtaken Europe as the preferred location for healthcare investing, according to a new report from Jefferies, published as the investment group's global conference gets underway in London today.
The annual Jefferies Healthcare Temperature Check – which polls senior healthcare executives and investors – found that while North America is still perceived as the greatest value opportunity for investment in the coming year, cited by 73% of respondents, China has climbed into second place, chosen by 47%. In comparison, Europe (excluding the UK) comes in third place with 27%, ahead of the UK on 13% and Japan on 8%.
The rapid rise of China – which was tied with Europe last year – comes on the back of record levels of biopharma out-licensing activity as global pharmaceutical companies seek access to new drug candidates, according to Jefferies. At the same time, the country's share of global commercial clinical trials has increased from 10% to 30% over the past decade, while Europe's share has declined from 18% to 9%.
"China is becoming increasingly important not only as an end market, but also as a source of scientific and commercial innovation," says the report.
M&A set to dominate healthcare deal-making in 2027
Corporate-led M&A activity is expected to dominate deal-making activity in the healthcare sector next year, with 58% of executives taking that view – up eight points on last year's survey – while equity financing remains "subdued."
Only 12% think private equity-backed M&A to be a major factor, and just 9% of respondents expect equity financing, including IPOs, to dominate healthcare transaction activity in 2027, continuing a decline from 20% in 2024.
Strategic dealmaking "continues to gather pace" as companies search for new sources of growth externally, according to Jefferies, with strategic buyers expected to be better positioned to pursue transactions as financial sponsors continue to navigate a more challenging fundraising, financing, and exit environment.
Among other findings are that mid- and small-cap pharma and biotech remains the publicly traded healthcare segment most widely expected to perform best over the next 12 months, ahead of large-cap pharma and biotech.
GLP-1-targeting drugs will continue to deliver sustained long-term growth, driven by new drug-delivery routes like oral formulations, and AI will deliver "tangible benefits" in health monitoring and predictive analytics, administrative efficiencies, and personalised medicine.
Geopolitics still a concern
Overall, the polled executives are positive on the outlook for the sector next year, despite the turmoil caused by inflation, rising interest rates, drug pricing initiatives, and geopolitical volatility that have featured strongly in 2026.
Geopolitical uncertainty remains the leading single risk facing the sector, selected by 38% of respondents, while 72% are very or somewhat concerned about its impact on their business or investments.
On the other hand, there continue to be positive developments across the industry, underlining healthcare's status as a defensive asset class, according to Jefferies.
"Overall, respondents are not retreating from healthcare. Rather, they are becoming more discerning about where value will emerge," concludes the report.
"The ability to combine innovation with scale, access to capital and commercial execution is likely to be increasingly important in determining performance in 2027."
Image by Gerd Altmann from Pixabay
